Vera Therapeutics announces CRO transition: Turner to Special Advisor, Bowman appointed Chief Regulatory Officer

Vera Therapeutics, Inc.

William Turner steps down as Chief Regulatory Officer, becomes Special Advisor for Regulatory Affairs effective August 3, 2026.
Nancy Bowman, M.D., Ph.D., appointed as new Chief Regulatory Officer, effective August 3, 2026.
Transition appears planned; no reason for departure given.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.